Form 6-K Sanofi For: Sep 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
September 4, 2025 10:03 AM EDTWilliam Blair on Sanofi (NASDAQ: SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'.
The analyst comments "On Thursday, September 4, Sanofi (SNY $49.89) reported the top-line results for the anti-OX40 ligand (OX40L) antibody amlitelimab in atopic dermatitis (AD) from the Phase III COAST 1 trial in a press release. The release included numerical results for the key efficacy endpoints, and full detailed results will be presented at a later... More
